Site blog

Picture of Meguid El Nahas
by Meguid El Nahas - Monday, 11 April 2011, 1:32 PM
Anyone in the world

Professor Neil Powe (USA) discussed the issue of healthcare disparities and inequalities in the USA where ethnic minorities have worse outcomes than Caucasians. he noted that by 2050, whites would be in a minority (<50%) in the USA; this already the case in certain cities such as San Francisco where Hispanics, Asians and African-Americans (AA) constitute the majority of the population. He reviewed the poorer outcomes of AA in CKD and higher prevalence in ESRD where they usually start RRT at a younger age than Whites. But he explained that such difference depends on modifiable factors and some such as genetic predisposition (MYH9 and APOL1 genetic polymorphism) which are not modifiable. The modifiable include low socio-economic status, lifestyle, access to care and care quality. 

For instance most Black patients with CKD are seen clinics and emergency rooms where they have no follow-ups as most don't have healthcare insurance. Whites on the other hand tend to be referred early to private healthcare facilities where they are treated and followed up. It is hoped that the new Healthcare system in the US may address some of these inequalities. If changes are allowed to go through and be implemented. Of note, the latest US government guidelines on CKD referral stress that patients should be referred "early" at CKD stages 4 and 5.....If that is early referral, I don't know what is late; probably the current situtation of more than 80% referred with GFR<20 within 3 months from starting RRT...?! Some talk about early detection and prevention of CKD in the US. Perhaps a place to start is to make sure that all those with CKD3 and proteinuria are detected and properly referred and treated...!!!  

[ Modified: Thursday, 1 January 1970, 1:00 AM ]

Comments

     
    Picture of Meguid El Nahas
    by Meguid El Nahas - Monday, 11 April 2011, 1:20 PM
    Anyone in the world

    Plenary lecture by Professor David Salant (USA) highlighting his discovery of the relevance of autoantibodies against the podocyte antigen M-type phospholipase A2 R, present on podocytes, to the pathogenesis of idiopathic membranous nephropathy (iMN) (Beck et al. 2009). These autoantiboides are specific to iMN and are not detectable in secondary forms of MN. They appear in high titres during the active phase of iMN with nephrotic syndrome and decrease considerably during treatment and remission; they reappear when the NS relapses. Up to 82% of patients with iMN have anti-PLA2R antibodies. Autoantibodies titre correlate with the severity of proteinuria in these patients. More recent data also showed a SNP mutation in the gene coding for PLA2R on chromosome 2 in patients with iMN, this along with another mutation on HLA DQ1A (Stanescu et al. 2011). 

     Of interest, another antibody directed against neutral endopeptidase (NEP) has been described in iMN (Professor P Ronco, Paris, France). This was observed in a woman deficient in this enzyme who was sensitised during a first pregancy and transmitted the antibody to her second born leading to a neonatal membranous nephropathy and nephrotic syndrome. Professor salant claimed that this antibody is seldom found in adults with iMN; I wonder whether Professor Ronco would have a different take on the whole story???!!! More research is also needed to determine what triggers the autoimmunity directed against podocytes PLA2R.

    [ Modified: Thursday, 1 January 1970, 1:00 AM ]

    Comments

       
      Picture of Meguid El Nahas
      by Meguid El Nahas - Sunday, 10 April 2011, 1:54 AM
      Anyone in the world

      Professor Ricardo Correa-Rotter from Mexico reviwed the issue of very high CKD and ESRD in central America. MesoAmerican Endemic Nephropathy. This has been attributed to a number of factors but more recently to involvements of those working in mining as well as farmers and agricultural workers dealing with sugar cane. The evidence for incriminating sugar cane is very limited (Torres et al, AJKD 2010). But a high incidence of CKD/ESRD in countries like El Salvador and Nicaragua is clearly observed with clinical features of chronic tubulointerstitial disease; small kidneys, low GFR and minimal proteinuria. Enviromental factors including soil pollution as well as exposure to minerals and heavy metals could be implicated. Clearly, this is an issue that warrants regional attention and research. It is reminiscent of the Balkan Endemic Nephropathy that was eventually attributed to contamination of soil and wheat by aristolochic acid. Aristolochic Associate Nephropathy (AAN) is not confined to the Balkans herbal remedies and intake contaminated with aristolochic acid can be seen all over the world and has been implicated in the very high incidence of CKD in Taiwan where herbal Mu Tong consumption contains AA. The latter does not seem to be involved in Central America.  

      [ Modified: Thursday, 1 January 1970, 1:00 AM ]

      Comments

         
        Picture of Meguid El Nahas
        by Meguid El Nahas - Sunday, 10 April 2011, 1:45 AM
        Anyone in the world

        Second plenary lecture by Prof Wendy Hoy (Australia) on the nephrological plight of Australian aborigines.

        Native australians are amongst the most deprived populations in the world. They suffer high morbidity and mortality rates. The incidence of ESRD in some of these populations exceeds 1000pmp/year!

        Prof Hoy argues that the high ioncidence and prevalence of CKD and ESRD in these populations is due to a number of factors: Multi-hits:

        Low birth weight and reduced nephrons number, later life hypertension, obesity and diabetes as well as repeated bouts of post-infectious glomerulonephritis. They express a strong association between albuminuria and all cause as well as CVD mortality. This fits with observations made in other populations stressing the links between poverty, inflammtion/infections, CVD and albuminuria. The latter is most likely to be a manifestations of the formers. She also reminded the audience of the association between chronic H. Pylori infections and the risk of microalbuminuria. Once more, albuminuria seems to be a marker of a number of underlying infectious, inflammatory as well as CV diseases.

        [ Modified: Thursday, 1 January 1970, 1:00 AM ]

        Comments

           
          Picture of Meguid El Nahas
          by Meguid El Nahas - Sunday, 10 April 2011, 1:38 AM
          Anyone in the world

          I attended two plenary lectures:

          The first by prof David Sacks on tolerance in renal transplantation. He highlighted the joruney related to research into induction of tolerance in recipients of allografts by T cell depletion followed by induction of chimerism through dual bone marrow an dkidney transplantationb. T cell depletion by using ATG seemed to deplete peripheral T cells but not those in lymph nodes or in the Thymus. So additional thymus irradiation may be needed. Also, T cell depletion alonbe may not be enough so additional B cell depletion with an anti-CD20 monoclonal antibody (Rituximab) may be necessary. Ultimately, such tolerance induction through chimerism has not been fully successful. He went on to discuss xenografting as an alternative to tolerance induction by chimerism. One of many problems with pig xenografting is that human develop anti-GAL antibodies that lead to hyperactute rejection. Advances have been made with transplantation of organs from pigs knock out to GAL making them more acceptable to humans. Also, chimerism with bone marrow + kidneys from pigs or kidneys + thymus (the thymus engrafted unde3r the renal capsule before transplantation) may improve outcomes. I personally don't see this research going anywhere; these researchers have been making these promising noises for the last 20 years to no avail...?! Better pharmacological induction of tolerance and better use of immunosuppressive agents is more likely to yield results in the short term. Early use of CNI but also early discontinuation of these agents and their replacement by less nephrotoxic agents may be a step in the right direction, providing alternate immunosuppression is effective with minimal side effects. 

          [ Modified: Thursday, 1 January 1970, 1:00 AM ]

          Comments

             
            Picture of Meguid El Nahas
            by Meguid El Nahas - Saturday, 9 April 2011, 2:59 PM
            Anyone in the world

            A truly spectacular lecture was given by Professor Douglas Wallace (Pennsylvania, USA) on mitochondrial disease and mtDNA mutations and their anthropological as well as medical implications. Professor Wallace explained hwo the mitochondria (an itracellular organelle/bacteria) invaded a eukariotic cells some 2 billion years ago during our evolution to produce this hybrid and symbiotic cell that we are made of. Consequently, we have the nuclear DNA but also the bacterial mitochondria DNA (mtDNA). He highlighted the key role in energy generation undertaken by the mitochondria; the main source of energy in power in our cells and in our body. He also showed how different capacity to generate or conserve energy in relation to intake (sugar/carbohydrates consumption) have evolved to adapt organisms and humans to live in different geographical parts of our planets. mtDNA can very accuraetly track human migration out of Africa and into the rest of the world with differing energy and mitochondrial phenotypes arising from the environment into which humans migrated. The mutation rate of mtDNA is 10 times higher than that of nuclear DNA because the mitochonderia lack protective histones and protective repair mechanisms. Kidney cells participate in many nergy-rich functions thus making the kidnye particularly suscpetible to mitochondrial damage and related disease. Professor Wallace pointed out to the huge nmber of diseases including common entities susch as hypertension and diabetes that may be influenced by mtDNA mutations; hypertension and its link to inflammtion and atherosclerosis; perhaps not consequential but linked to a mtDNA mutations, similarly diabetes mellitus and nephropathy; perhaps a mtDNA mutation predisposing to both. So increased awareness of this cellular/mitochondrial genome compared to the nuclear one may unravel the secret of many conditions not fully explained by nuclear genes mutations.

            [ Modified: Thursday, 1 January 1970, 1:00 AM ]

            Comments

               
              Anyone in the world

              Jungraithmayr and colleagues in the March issue of JASN report the interesting observation that patients with FSGS and a SNP mutation in the NPHS2 gene coding for the podocyte protein (podocin) seem somewhat protected from NS and FSGS recurrence after renal transplantation compared to a recurrence rate of 48% in those without the mutations. This is of considerable interest as the recurrence rate and graft loss in FSGS recipients of renal allograft is high (around 30-40%) with a limited number of known predicotrs of recurrence. It is clear that those with a recurrence in a first graft are at higher risk of recurrence in the second. Other factors are more controversial; such as young age at transplantation, a rapid decline in CKD before transplantation etc... So this paper adds a useful predictor suggesting that the recipient should be screened for NPHS2 mutations (protective) but also that the donor to a mutation positive recipient should also be screened. Of note others (Bertelli et al. 2003) found an equal recurrence rate in geneitc versus non-genetic FSGS. Clearly, the debate and investigations continue.  

              [ Modified: Thursday, 1 January 1970, 1:00 AM ]

              Comments

                 
                Picture of Arif Khwaja
                by Arif Khwaja - Monday, 4 April 2011, 9:36 AM
                Anyone in the world

                Data from the DAC Graft Trial, in which 649 patients were assigned to either placebo or twice-daily extended-release dipyridamole (200 mg) and Aspirin (ASA) (25 mg; ERDP/ASA) after AV graft placement suggested that ERDP/ASA lead to a very modest, but significant reduction in graft thrombosis/need for graft angioplasty. Now a recent analyis of this study suggests compared outcomes associated with ASA  use across and within randomized groups assigned to either ERDP/ASA or placebo. Thee key finding was that ERDP/ASA was no more effective than ASA onlone in preventing graft thrombosis/angioplasty. The message therefore is that Aspirin should be used in all patients with grafts but the benefits are modest. Vascular access remains a critical problem on dialysis units - share your thoughts. See accompanying editorial in JASN (http://www.ncbi.nlm.nih.gov/pubmed/21415154)

                [ Modified: Thursday, 1 January 1970, 1:00 AM ]

                Comments

                   
                  Picture of Arif Khwaja
                  by Arif Khwaja - Thursday, 31 March 2011, 9:57 AM
                  Anyone in the world

                  A very thoughtful piece by Professor Chapman from Sydney, Australia in this months AJT reviewing the literature around CNI nephrotoxicity ( see here ) Professor Chapman confirms the notion that whilst CNIs reduce the incidence of acute rejection the long term impact on graft function is significant especially in grafts older than 5 years. Furthermore nephrotoxoicity seems to be dose related. Attempts to manage immunsuppresion without CNIs have been variable. At present CNIs remain a 'cant live with you and cant live without you' medication in transplantation with CNI nephrotoxicity competing with other causes of longterm graft loss such as chronic transplant glomerulopathy.

                  [ Modified: Thursday, 1 January 1970, 1:00 AM ]

                  Comments

                     
                    Picture of Arif Khwaja
                    by Arif Khwaja - Monday, 21 March 2011, 12:50 PM
                    Anyone in the world

                    There is an interesting article in this months cJASN analysing the effect of using the CKD-EPI formula (rather than the MDRD equation) on eGFR calculation and therefore CKD diagnosis. The CKD-EPI formula is believed to be more accurate than MDRD when the eGFR>60mls/min. Interestingly in an analysis of 53,759 patients with CKD 3-5 the authors compared the effect of CKD-EPI and MDRD equations on CKD diagnosis. Interestingly there was a 35% decrease in the diagnosis of CKD among patients 90 years. Women, non-African Americans, nondiabetics, and obese patients were less likely to be classified on the basis of CKD-EPI. in a way the research highlights the problem of 'disease-labelling' that has occured as a result of the CKD staging system and further highlights the paradox of differentiating CKD 1 and 2 on the basis of the MDRD equation when this equation is known to be inaccurate when the eGFR>60mls/min. See Implications of the CKD-EPI GFR Estimation Equation in Clinical Practice in this months cJASN. share your thoughts on the merits or otherwise of the CKD classification system and MDRD equation.

                    [ Modified: Thursday, 1 January 1970, 1:00 AM ]

                    Comments